This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...

A combination of genes either knocked out or activated by CRISPR promises to be a general and straightforward way to obtain high-yielding crops fully...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.

Some of the best links we picked up around the internet

Just as the summer was creeping in, we hosted our most popular CMN webinar to date. The topic was CRISPR Off-Targets with speakers from academia and a...

This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.